The World Health Organization (WHO) will meet on Tuesday to consider approval for the coveted emergency use of Covaxin, India’s vaccine against coronavirus disease (Covid-19). According to WHO Chief Scientist Soumya Swaminathan, the World Health Organization’s technical advisory group will meet on October 26 to review the Emergency Use List (EUL) for Covaxin, which is already in use. nationwide in the pandemic vaccination campaign.
The World Health Organization (WHO) will meet today to consider granting emergency use approval for Covaxin. According to WHO Chief Scientist Soumya Swaminathan, the technical advisory group will meet to grant an Emergency Use List (EUL) for Covaxin.
The world health agency has also stressed that it must evaluate a vaccine thoroughly to ensure that it is “safe and effective”.
Hyderabad-based Bharat Biotech, which developed Covaxin, had submitted an EOI (expression of interest) to the WHO on April 19 for the vaccine’s Emergency Use List (EUL).
In a series of tweets, the WHO said: “We are aware that many people are waiting for the WHO recommendation for Covaxin to be included in the # COVID-19 emergency use list, but we cannot not cut corners – before recommending a product for emergency use, we must evaluate it thoroughly to make sure it is safe and effective. “
He also said that Bharat Biotech has submitted data to the WHO on an ongoing basis and that WHO experts have reviewed this data.
“WHO is now awaiting additional information from the company,” he said.
“When the information provided answers all the questions raised, WHO and the technical advisory group will complete the assessment and make a final recommendation on whether to grant EUL to the vaccine,” he said.
WHO has said that the timing of its EUL procedure depends on how quickly a company producing the vaccine is able to provide the data needed by WHO to assess the quality, safety, efficacy and effectiveness. vaccine suitability for low- and middle-income countries.
Covaxin is one of two COVID vaccines used by India in its nationwide vaccination campaign.
Earlier this month, the WHO tweeted that Bharat Biotech “has submitted data to WHO on an ongoing basis and submitted additional information, on September 27. WHO experts are currently reviewing these information and if they answer all the questions raised, the WHO assessment will be finalized next week. “
Rolling data allows WHO to begin its review immediately, as information continues to arrive, to speed up the overall review process.
According to the WHO, submissions for prequalification or registration under the GUE procedure are confidential and if a product submitted for evaluation is found to meet the criteria for registration, the WHO will publish the results widely.
Never miss a story! Stay connected and informed with Mint. Download our app now !!